Overview

Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial

Status:
Active, not recruiting

Trial end date:
2021-08-30

Target enrollment:

Participant gender:

Summary

The Michelle trial is expected to provide high-quality evidence around the role of extended thromboprophylaxis in COVID-19 and will help guide medical decisions in clinical practice.

Phase:

Phase 3

Details

Lead Sponsor:

Science Valley Research Institute

Collaborator:

Bayer

Treatments:

Rivaroxaban